The Aurora Kinase A pipeline drugs market research report outlays comprehensive information on the Aurora Kinase A targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Aurora Kinase A pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, and Immunology which include the indications Small-Cell Lung Cancer, Triple-Negative Breast Cancer (TNBC), and Graft Versus Host Disease (GVHD). It also reviews key players involved in Aurora Kinase A targeted therapeutics development with respective active and dormant or discontinued products.
The Aurora Kinase A pipeline targets constitutes close to 16 molecules. Out of which, approximately 11 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, IND/ CTA Filed, Preclinical, and Discovery stages are 5, 2, 3, and 1 respectively. Similarly, the universities portfolio in Preclinical comprises 5 molecule.
Aurora Kinase A overview
Aurora kinase A also known as serine/threonine-protein kinase 6 is an enzyme that contributes to the regulation of cell cycle progression. It plays a critical role in various mitotic events including the establishment of mitotic spindle, centrosome duplication, centrosome separation as well as maturation, chromosomal alignment, spindle assembly checkpoint, and cytokinesis. It is required for initial activation of CDK1 at centrosomes and normal axon formation. It phosphorylates numerous target proteins, including ARHGEF2, BORA, BRCA1, CDC25B, DLGP5, HDAC6, KIF2A, LATS2, NDEL1, PARD3, PPP1R2, PLK1, RASSF1, TACC3, p53/TP53 and TPX2. It regulates KIF2A tubulin depolymerase activity.
For a complete picture of Aurora Kinase A’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
